Metabolic syndrome: A major risk factor for atherosclerosis in HIV-infected patients (SHIVA study)

Presse Medicale

Volumn 37, Issue 4 PART 1, 2008, Pages 579-584

  Martin, Luc de Saint ^a   Pasquier, Elisabeth ^a   Roudaut, Nathalie ^a   Vandhuick, Olivier ^a   Vallet, Sophie ^a   Bellein, Véronique ^a   Bressollette, Luc ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTERY INTIMA; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT; PREVALENCE; RANK SUM TEST; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 40949158756     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.09.022     Document Type: Article

References (22)

1. Friis-Moller N., Weber R., Reiss P., Thiebaut R., Kirk O., d'Arminio Monforte A., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17 (2003) 1179-1193
2. Sweet D.E. Metabolic complications of antiretroviral therapy. Top HIV Med 13 (2005) 70-74
3. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res 4 (2006) 79-85
4. Ninomiya J.K., L'Italien G., Criqui M.H., Whyte J.L., Gamst A., and Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109 (2004) 42-46
5. de Saint Martin L., Vandhuick O., Guillo P., Bellein V., Bressollette L., Roudaut N., et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (Shiva study). Atherosclerosis 185 (2006) 361-367
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-96.
7. Aminbakhsh A., and Mancini G.B. Carotid intima-media thickness measurements: what defines an abnormality? A systematic review. Clin Invest Med 22 (1999) 149-157
8. Hadigan C., Meigs J.B., Wilson P.W.F., D'Agostino R.B., Davis B., Basgoz N., et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 36 (2003) 909-916
9. Gazzaruso C., Sacchi P., Garzaniti A., Fratino P., Bruno R., and Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 25 (2002) 1253-1254
10. Jerico C., Knobel H., Montero M., Ordonez-Llanos J., Guelar A., Gimeno J.L., et al. Metabolic Syndrome Among HIV-Infected Patients Prevalence, characteristics, and related factors. Diabetes Care 28 (2005) 132-137
11. Maumus S., Marie B., Siest G., and Visvikis-Siest S. A prospective study on the prevalence of metabolic syndrome among healthy French families. Diabetes Care 28 (2005) 675-682
12. Joly V., Flandre P., Meiffredy V., Leturque N., Harel M., Aboulker J.P., et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 16 (2002) 2447-2454
13. Hirsch H.H., and Battegay M. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection 30 (2002) 293-298
14. Asztalos B.F., Schaefer E.J., Horvath K.V., Cox C.E., Skinner S., Gerrior J., et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis 184 (2006) 72-77
15. Thiebaut R., El-Sadr W.M., Friis-Moller N., Rickenbach M., Reiss P., Monforte A.D., et al. Data Collection of Adverse events of anti-HIV Drugs Study Group. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther 10 (2005) 811-823
16. Jacobson D.L., Knox T., Spiegelman D., Skinner S., Gorbach S., and Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 40 (2005) 1837-1845
17. Bogner J.R., Vielhauer V., Beckmann R.A., Michl G., Wille L., Salzberger B., et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 27 (2001) 237-244
18. Fisac C., Fumero E., Crespo M., Roson B., Ferrer E., Virgili N., et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 19 (2005) 917-925
19. Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165 (2005) 1179-1184
20. El-Sadr W.M., Mullin C.M., Carr A., Gibert C., Rappoport C., Visnegarwala F., et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 6 (2005) 114-121
21. Guerrero-Romero F., and Rodriguez-Moran M. Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. Diabetes Care 28 (2005) 2588-2589
22. Saely C.H., Koch L., Schmid F., Marte T., Aczel S., Langer P., et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 29 (2006) 901-907